{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:33:46Z","timestamp":1788557626213,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,25]]},"DOI":"10.7759\/cureus.49390","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T17:37:10Z","timestamp":1700933830000},"source":"Crossref","is-referenced-by-count":11,"title":["The Pathogenesis and Treatment of Hidradenitis Suppurativa"],"prefix":"10.7759","author":[{"given":"Erica R","family":"Agnese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Tariche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24755","article-title":"Hidradenitis suppurativa in the United States: insights from the National Inpatient Sample (2008-2017) on contemporary trends in demographics, hospitalization rates, chronic comorbid conditions, and mortality","volume":"14","author":"Patel A","year":"2022","unstructured":"Patel A, Patel A, Solanki D, Mansuri U, Singh A, Sharma P, Solanki S. Hidradenitis suppurativa in the United States: insights from the National Inpatient Sample (2008-2017) on contemporary trends in demographics, hospitalization rates, chronic comorbid conditions, and mortality. Cureus. 2022, 14:e24755. 10.7759\/cureus.24755","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen TV","year":"2021","unstructured":"Nguyen TV, Damiani G, Orenstein LA, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021, 35:50-61. 10.1111\/jdv.16677","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/life11010034","article-title":"Quality-of-life impairment among patients with hidradenitis suppurativa: a cross-sectional study of 1795 patients","volume":"11","author":"Krajewski PK","year":"2021","unstructured":"Krajewski PK, Matusiak \u0141, von Stebut E, Schultheis M, Kirschner U, Nikolakis G, Szepietowski JC. Quality-of-life impairment among patients with hidradenitis suppurativa: a cross-sectional study of 1795 patients. Life (Basel). 2021, 11:34. 10.3390\/life11010034","journal-title":"Life (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.08.090","article-title":"Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis","volume":"82","author":"Goldburg SR","year":"2020","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020, 82:1045-58. 10.1016\/j.jaad.2019.08.090","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23029","article-title":"Hidradenitis suppurativa: estimated prevalence, clinical features, and risk factors in Riyadh, Saudi Arabia","volume":"14","author":"Alsadhan H","year":"2022","unstructured":"Alsadhan H, Alfawzan AI, Yaqoub A, Almoneef A, Almohideb M. Hidradenitis suppurativa: estimated prevalence, clinical features, and risk factors in Riyadh, Saudi Arabia. Cureus. 2022, 14:e23029. 10.7759\/cureus.23029","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15579","article-title":"Hidradenitis suppurativa: pathogenesis, clinical presentation, epidemiology, and comorbid associations","volume":"60","author":"Preda-Naumescu A","year":"2021","unstructured":"Preda-Naumescu A, Ahmed HN, Mayo TT, Yusuf N. Hidradenitis suppurativa: pathogenesis, clinical presentation, epidemiology, and comorbid associations. Int J Dermatol. 2021, 60:e449-58. 10.1111\/ijd.15579","journal-title":"Int J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa ?-15 years after","volume":"29","author":"Zouboulis CC","year":"2020","unstructured":"Zouboulis CC, Benhadou F, Byrd AS, et al.. What causes hidradenitis suppurativa ?-15 years after. Exp Dermatol. 2020, 29:1154-70. 10.1111\/exd.14214","journal-title":"Exp Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319830646","article-title":"Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms","volume":"10","author":"Frew JW","year":"2019","unstructured":"Frew JW, Hawkes JE, Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019, 10:2040622319830646. 10.1177\/2040622319830646","journal-title":"Ther Adv Chronic Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2022.08.024","article-title":"Patient perspectives on diagnosis and management of hidradenitis suppurativa: a web-based survey","volume":"9","author":"Hsiao JL","year":"2022","unstructured":"Hsiao JL, Shi VY, Muscianisi E, Nguyen E, Darcy J 2nd, Kirby JS. Patient perspectives on diagnosis and management of hidradenitis suppurativa: a web-based survey. JAAD Int. 2022, 9:139-41. 10.1016\/j.jdin.2022.08.024","journal-title":"JAAD Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations","volume":"86","author":"Garg A","year":"2022","unstructured":"Garg A, Malviya N, Strunk A, et al.. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations. J Am Acad Dermatol. 2022, 86:1092-101. 10.1016\/j.jaad.2021.01.059","journal-title":"J Am Acad Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14563","article-title":"Impact of psychiatric comorbidities in psoriasis, hidradenitis suppurativa and atopic dermatitis: the importance of a psychodermatological approach","volume":"31","author":"Iannone M","year":"2022","unstructured":"Iannone M, Janowska A, Panduri S, Morganti R, Davini G, Romanelli M, Dini V. Impact of psychiatric comorbidities in psoriasis, hidradenitis suppurativa and atopic dermatitis: the importance of a psychodermatological approach. Exp Dermatol. 2022, 31:956-61. 10.1111\/exd.14563","journal-title":"Exp Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2021.0051","article-title":"Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs","volume":"5","author":"Collier F","year":"2021","unstructured":"Collier F, Howes R, Rodrigues J, Thomas KS, Leighton P, Ingram JR. Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. BJGP Open. 2021, 5:BJGPO.2021.0051. 10.3399\/BJGPO.2021.0051","journal-title":"BJGP Open"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12770","article-title":"Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1","volume":"59","author":"Vekic DA","year":"2018","unstructured":"Vekic DA, Frew J, Cains GD. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1. Australas J Dermatol. 2018, 59:267-77. 10.1111\/ajd.12770","journal-title":"Australas J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13107","article-title":"A gene dysfunction module reveals the underlying pathogenesis of hidradenitis suppurativa: an update","volume":"61","author":"Li X","year":"2020","unstructured":"Li X, Jiang L, Huang Y, Ren Z, Liang X, Wang P. A gene dysfunction module reveals the underlying pathogenesis of hidradenitis suppurativa: an update. Australas J Dermatol. 2020, 61:e10-4. 10.1111\/ajd.13107","journal-title":"Australas J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101371","article-title":"Transcriptome meta-analysis confirms the hidradenitis suppurativa pathogenic triad: upregulated inflammation, altered epithelial organization, and dysregulated metabolic signaling","volume":"12","author":"de Oliveira AS","year":"2022","unstructured":"de Oliveira AS, Bloise G, Moltrasio C, et al.. Transcriptome meta-analysis confirms the hidradenitis suppurativa pathogenic triad: upregulated inflammation, altered epithelial organization, and dysregulated metabolic signaling. Biomolecules. 2022, 12:1371. 10.3390\/biom12101371","journal-title":"Biomolecules"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315250","article-title":"The role of hormones in hidradenitis suppurativa: a systematic review","volume":"23","author":"Abu Rached N","year":"2022","unstructured":"Abu Rached N, Gambichler T, Dietrich JW, Ocker L, Seifert C, Stockfleth E, Bechara FG. The role of hormones in hidradenitis suppurativa: a systematic review. Int J Mol Sci. 2022, 23:15250. 10.3390\/ijms232315250","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179716","article-title":"Immunomodulatory drugs in the treatment of hidradenitis suppurativa-possibilities and limitations","volume":"23","author":"\u015awierczewska Z","year":"2022","unstructured":"\u015awierczewska Z, Lewandowski M, Surowiecka A, Bara\u0144ska-Rybak W. Immunomodulatory drugs in the treatment of hidradenitis suppurativa-possibilities and limitations. Int J Mol Sci. 2022, 23:9716. 10.3390\/ijms23179716","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2018.7546","article-title":"Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome)","volume":"10","author":"Melibary YT","year":"2018","unstructured":"Melibary YT. Hidradenitis suppurativa in a patient with hyperandrogenism, insulin-resistance and acanthosis nigricans (HAIR-AN syndrome). Dermatol Reports. 2018, 10:7546. 10.4081\/dr.2018.7546","journal-title":"Dermatol Reports"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/life11070697","article-title":"The role of oral contraceptive pills in hidradenitis suppurativa: a cohort study","volume":"11","author":"Montero-Vilchez T","year":"2021","unstructured":"Montero-Vilchez T, Valenzuela-Amigo A, Cuenca-Barrales C, Arias-Santiago S, Leyva-Garc\u00eda A, Molina-Leyva A. The role of oral contraceptive pills in hidradenitis suppurativa: a cohort study. Life (Basel). 2021, 11:697. 10.3390\/life11070697","journal-title":"Life (Basel)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10082039","article-title":"Hidradenitis suppurativa: a perspective on genetic factors involved in the disease","volume":"10","author":"Moltrasio C","year":"2022","unstructured":"Moltrasio C, Tricarico PM, Romagnuolo M, Marzano AV, Crovella S. Hidradenitis suppurativa: a perspective on genetic factors involved in the disease. Biomedicines. 2022, 10:2039. 10.3390\/biomedicines10082039","journal-title":"Biomedicines"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030670","article-title":"Efficacy and toxicity of classical immunosuppressants, retinoids and biologics in hidradenitis suppurativa","volume":"11","author":"Das K","year":"2022","unstructured":"Das K, Daveluy S, Kroumpouzos G, et al.. Efficacy and toxicity of classical immunosuppressants, retinoids and biologics in hidradenitis suppurativa. J Clin Med. 2022, 11:670. 10.3390\/jcm11030670","journal-title":"J Clin Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211055920","article-title":"New perspectives on the treatment of hidradenitis suppurativa","volume":"12","author":"Amat-Samaranch V","year":"2021","unstructured":"Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2021, 12:20406223211055920. 10.1177\/20406223211055920","journal-title":"Ther Adv Chronic Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237240","article-title":"Current medical and surgical treatment of hidradenitis suppurativa-a comprehensive review","volume":"11","author":"Ocker L","year":"2022","unstructured":"Ocker L, Abu Rached N, Seifert C, Scheel C, Bechara FG. Current medical and surgical treatment of hidradenitis suppurativa-a comprehensive review. J Clin Med. 2022, 11:7240. 10.3390\/jcm11237240","journal-title":"J Clin Med"},{"key":"ref24","unstructured":"Stages of Hidradenitis Suppurativa. (2023). Accessed. September 14, 2023: http:\/\/www.shutterstock.com\/image-vector\/boil-cyst-acne-swollen-cancer-ingrown-2012209205."},{"key":"ref25","unstructured":"Hidradenitis Suppurativa (HS). (2023). Accessed. September 14, 2023: http:\/\/www.shutterstock.com\/image-photo\/hidradenitis-suppurativa-hs-sometimes-known-acne-147990653."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911280","article-title":"Microbiome in hidradenitis suppurativa-what we know and where we are heading","volume":"23","author":"\u015awierczewska Z","year":"2022","unstructured":"\u015awierczewska Z, Lewandowski M, Surowiecka A, Bara\u0144ska-Rybak W. Microbiome in hidradenitis suppurativa-what we know and where we are heading. Int J Mol Sci. 2022, 23:11280. 10.3390\/ijms231911280","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1159\/000507323","article-title":"Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice","volume":"236","author":"Orenstein LA","year":"2020","unstructured":"Orenstein LA, Nguyen TV, Damiani G, Sayed C, Jemec GB, Hamzavi I. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology. 2020, 236:393-412. 10.1159\/000507323","journal-title":"Dermatology"},{"key":"ref28","unstructured":"FDA Approves Novartis Cosentyx\u00ae as the First New Biologic Treatment Option for Hidradenitis Suppurativa Patients in Nearly a Decade. (2023). Accessed. November 13, 2023: https:\/\/www.novartis.com\/news\/media-releases\/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidra...."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00725-9","article-title":"Drug survival of oral retinoids in hidradenitis suppurativa: a real-life cohort study","volume":"23","author":"Bouwman K","year":"2022","unstructured":"Bouwman K, Aarts P, Dudink K, et al.. Drug survival of oral retinoids in hidradenitis suppurativa: a real-life cohort study. Am J Clin Dermatol. 2022, 23:905-14. 10.1007\/s40257-022-00725-9","journal-title":"Am J Clin Dermatol"},{"key":"ref30","article-title":"Surgical management of hidradenitis suppurativa: a narrative review","volume":"15","author":"Chawla S","year":"2022","unstructured":"Chawla S, Toale C, Morris M, Tobin A, Kavanagh D. Surgical management of hidradenitis suppurativa: a narrative review. J Clin Aesthet Dermatol. 2022, 15:35-41.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000004569","article-title":"Our experience in using lateral chest flap to treat axillary hidradenitis suppurativa","volume":"10","author":"Lahham SA","year":"2022","unstructured":"Lahham SA, Aljassem G, Omari RY, et al.. Our experience in using lateral chest flap to treat axillary hidradenitis suppurativa. Plast Reconstr Surg Glob Open. 2022, 10:e4569. 10.1097\/GOX.0000000000004569","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.04.034","article-title":"Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting","volume":"89","author":"Aarts P","year":"2023","unstructured":"Aarts P, van Huijstee JC, van der Zee HH, van Doorn MB, van Straalen KR, Prens EP. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting. J Am Acad Dermatol. 2023, 89:677-84. 10.1016\/j.jaad.2023.04.034","journal-title":"J Am Acad Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/204594-the-pathogenesis-and-treatment-of-hidradenitis-suppurativa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:10:24Z","timestamp":1707509424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/204594-the-pathogenesis-and-treatment-of-hidradenitis-suppurativa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.49390","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,25]]}}}